



Director Resignation and Appointment

Melbourne, Australia, 28 November 2024 – InhaleRx Ltd (ASX: IRX), (**'IRX'** or **'the Company'**) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises of the resignation of Dr Andrew Saich as a director of the Company and the appointment of Dr Ronald Wise as a director of the Company, effective immediately.

Dr Saich has informed the Board of his resignation due to a significant recent increase in time commitments related to his other business interests in the UK and Europe.

The Company has been conducting a search for additional directors to join the IRX board with a view to complementing the board's existing skills and experience. Dr Wise was identified as a standout candidate with the skills and experience within the scientific and drug development sectors to help guide IRX on the next stage of its growth as a drug development company.

Dr Ronald Wise holds a PhD (Plasma Proteins of Neonatal Animal) and a B Sc from the University of Western Australia. He completed 4 years post-doctoral research in the USA at FSU and Stanford University. He then lectured at UWA in the Department of Biochemistry for 2 years, followed by research at Princess Margaret Children's Hospital in WA.

Ron then became involved in mineral exploration and was Chairman of companies responsible for discovering the Woodada Gas Field and the Mt Percy Gold Mine. Then, as a founder of Exergy Inc, he spent 10 years helping develop the Kalina Cycle, a technology currently owned and being developed by Kalina Power Ltd, (ASX: KPO).

In recent times he has been involved as Chairman and co-founder of Selvax Pty Ltd, an immunotherapy drug development company, which is expanding on work carried out by the team of Dr Delia Nelson at Curtin University. Selvax has very recently achieved some outstanding success in developing antibodies to a number of hard tumour cancers.

Over the past 34 years, Ron has developed his passion for wine into a Halliday 5 star, family-owned winery in the Margaret River Region of WA.

The Board thanks Dr Saich for his contribution as a director since his appointment in July 2021 and wishes him every success in his future endeavours. An Appendix 3Z for Dr Saich and Appendix 3X for Dr Wise are attached to this announcement.

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary
Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders. The first medical indications under investigation are Breakthrough Cancer Pain ('**BTcP**') and Panic Disorder ('**PD**'), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: INHALERX LIMITED
ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DR RONALD WISE
Date of appointment	28 NOVEMBER 2024

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
SASSEY PTY LTD <SASSEY A/C>	2,192,985 IRX ORDINARY SHARES
SASSEY PTY LTD <AVAGO SUPER FUND A/C>	300,000 IRX ORDINARY SHARES
DR WISE IS A BENEFICIARY OF BOTH ENTITIES	TOTAL: 2,492,985 IRX ORDINARY SHARES

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: INHALERX LIMITED
ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	DR ANDREW SAICH
Date of last notice	20 JULY 2021
Date that director ceased to be director	28 NOVEMBER 2024

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
	Nil

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.